research Generic competition and pharma patent strategies - a sequel
The article concludes that recent legal rulings have strengthened the protection of pharmaceutical patents against generic competition.
Search
forResearch
5 / 1000+ results 
research The Pharma Market as Reflected by Patents
The document shows the state of pharmaceutical patents as of 1999, focusing on treatments for various diseases.
research Abstracts of the Final Year Projects of Pharm D Clinical Pharmacy Students Faculty of Pharmacy Beni-suef University Year 2024/2025
Healthcare professionals need better training and systems for drug interaction reporting, injectable vitamin B12 helps tingling, oral helps numbness, probiotics may help ulcerative colitis, and more research is needed on Post-Finasteride Syndrome.
research ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
ONCO-NK-TRANSITION-GM1 is a low-cost, effective cancer treatment with a high cure rate and no severe side effects.
research ONCO-NK-TRANSITION-GM1: The Bridge Cancer Therapy Manufacturable by Current Pharmaceutical Industry — 60-80% Cure Rate — $50 per Dose A Complete Transitional Drug from Full N‑K GM Series to Current Pharma Capability
ONCO-NK-TRANSITION-GM1 is a low-cost, effective cancer treatment with a high cure rate and no severe side effects.
Community Join
5 / 629 resultscommunity Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.
community Cosmo Pharma 2025 Investor Day Report
Cosmo Pharma plans to release Breezula, a hair loss treatment, with expected FDA approval in 2027, but concerns arise over its high potential cost of $225/month. Users express skepticism about its effectiveness compared to cheaper alternatives like finasteride and minoxidil.
community Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
community Coegin Pharma to release Follicopeptide (FOL005) by Q2 2025
Follicopeptide (FOL005) by Coegin Pharma will launch as a cosmetic hair growth treatment by Q2 2025, showing similar efficacy to finasteride. Users discuss the benefits and skepticism of releasing hair loss treatments as cosmetics rather than drugs.
Learn
2 / 801 resultslearn Overview
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Clinics
2 / 11 results
Experts
— no results